2Seventy Bio Non Current Liabilities Total Over Time

TSVT Stock  USD 4.96  0.01  0.20%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out 2Seventy Bio Performance and 2Seventy Bio Correlation.
For more information on how to buy 2Seventy Stock please use our How to Invest in 2Seventy Bio guide.
  
Non Current Liabilities Total is likely to gain to about 252.4 M in 2025.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of 2Seventy Bio. If investors know 2Seventy will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about 2Seventy Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.83)
Revenue Per Share
0.725
Quarterly Revenue Growth
(0.73)
Return On Assets
(0.13)
Return On Equity
(0.25)
The market value of 2Seventy Bio is measured differently than its book value, which is the value of 2Seventy that is recorded on the company's balance sheet. Investors also form their own opinion of 2Seventy Bio's value that differs from its market value or its book value, called intrinsic value, which is 2Seventy Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because 2Seventy Bio's market value can be influenced by many factors that don't directly affect 2Seventy Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between 2Seventy Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if 2Seventy Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, 2Seventy Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Non Current Liabilities Total Analysis

Compare 2Seventy Bio and related stocks such as Intercept Pharmaceuticals, Puma Biotechnology, and Iovance Biotherapeutics Non Current Liabilities Total Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Shareholders Equity Per ShareDebt To Equity
Capex Per ShareGraham Net Net
Average ReceivablesRevenue Per Share
Interest Debt Per ShareDebt To Assets
Enterprise Value Over E B I T D AShort Term Coverage Ratios
Price Earnings RatioOperating Cycle
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Cash Conversion CycleOperating Cash Flow Sales Ratio
Days Of Inventory OutstandingDays Of Sales Outstanding
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Enterprise Value MultipleDebt Ratio
Cash Flow To Debt RatioPrice Sales Ratio
Return On AssetsAsset Turnover
Net Profit MarginGross Profit Margin
Price Fair ValueReturn On Equity
2010201120122013201420152016201720182019202020212022202320242025
PBYI439.4 K439.4 K1.1 M1.1 M1.3 M1.4 M5.5 M53.9 M157.7 M126.6 M135.9 M119.4 M123 M77.7 M25.1 M23.8 M
IOVA0.00.00.00.00.00.00.00.0230 K6.6 M57.1 M66.5 M84.4 M85.4 M77.7 M46.2 M
SRPT3.1 M2.8 M2.4 M8.4 M10.5 M21.1 M12 M430.4 M436.1 M739.9 M1.8 B1.8 B2.1 B1.8 B1.7 B1.8 B
DAWN30.5 M30.5 M30.5 M30.5 M30.5 M30.5 M30.5 M30.5 M30.5 M30.5 M92.2 M16 K408 K0.06.6 M6.3 M
INZY55 M55 M55 M55 M55 M55 M55 M55 M55 M77.9 M1.3 M2.6 M6.1 M45.7 M31.5 M25.2 M
ZNTL2.5 M2.5 M2.5 M2.5 M2.5 M2.5 M2.5 M2.5 M2.5 M4.2 M3.6 M46.1 M48.6 M44.9 M51.7 M27.5 M
SNDX5.7 M5.7 M5.7 M2.5 M8.2 M18.4 M14.5 M17.1 M14.8 M13.6 M29.6 M20.6 M722 K588 K229.6 M241.1 M
PTGXMMMMM2.1 M0.0547 K799 K39.5 M4.6 M3.7 M784.7 M221 K22 M20.9 M
CGEM54 M54 M54 M54 M54 M54 M54 M54 M54 M137.8 M276.7 M65 K3.6 M2.1 M849 K806.5 K
MRSN46.4 M46.4 M46.4 M46.4 M46.4 M46.4 M132.3 M28.8 M282 K5.2 M15.3 M36.8 M150.8 M125.5 M91.7 M69.6 M
RLAY532.7 M532.7 M532.7 M532.7 M532.7 M532.7 M532.7 M532.7 M532.7 M561.5 M22.9 M86.3 M85.8 M61.7 M42.8 M40.6 M
RCUS4.7 M4.7 M4.7 M4.7 M4.7 M4.7 M4.7 M23.9 M23 M16.6 M148.3 M584.4 M495 M449 M439 M266.9 M
STOK16 K16 K16 K16 K16 K16 K16 K16 KK221 K422 K3.9 M39.8 M38 M2.5 M2.4 M
KZR28.2 M28.2 M28.2 M28.2 M28.2 M28.2 M28.2 M78.4 M2.5 M5.5 M4.4 M12.8 M18.7 M15.9 M7.4 M7.1 M
PHAT0.00.00.00.00.00.00.00.00.025.5 M45.3 M98.4 M213.4 M447.8 M546.2 M573.5 M
REPL32.3 M32.3 M32.3 M32.3 M32.3 M32.3 M32.3 M88.1 M6.6 M38.5 M29.8 M29.2 M57.5 M72.8 M83.7 M48.8 M
PLRX62.3 M62.3 M62.3 M62.3 M62.3 M62.3 M62.3 M62.3 M62.3 M111.3 M866 K5.3 M13.4 M10.1 M59.6 M30 M
CRNX17.9 M17.9 M17.9 M17.9 M17.9 M17.9 M17.9 M29.7 M3.3 M4.9 MM3.1 M8.1 M52.3 M50.1 M52.6 M
ASND213 K213 K23.8 M20 M12.9 M11.4 M13.2 M23.8 M26.6 M31.6 M88.3 M100.9 M655.1 M773.9 M377.3 M396.2 M

2Seventy Bio and related stocks such as Intercept Pharmaceuticals, Puma Biotechnology, and Iovance Biotherapeutics Non Current Liabilities Total description

My Equities

My Current Equities and Potential Positions

2Seventy Bio
TSVT
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationMassachusetts; U.S.A
ExchangeNASDAQ Exchange
USD 4.96

Additional Tools for 2Seventy Stock Analysis

When running 2Seventy Bio's price analysis, check to measure 2Seventy Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 2Seventy Bio is operating at the current time. Most of 2Seventy Bio's value examination focuses on studying past and present price action to predict the probability of 2Seventy Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 2Seventy Bio's price. Additionally, you may evaluate how the addition of 2Seventy Bio to your portfolios can decrease your overall portfolio volatility.